Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi : Regeneron, Sanofi Say Lung Cancer Drug Libtayo Improves Overall Patient Survival in Late-Stage Study

09/20/2021 | 04:24am EDT


© MT Newswires 2021
All news about SANOFI
11:50aSANOFI : says its flu vaccine can be co-administered with Moderna's COVID-19 shot
RE
11:50aSanofi in cdc presentation says study results demonstrate that its flu vaccine & modern..
RE
07:00aCigna's pharmacy benefit unit to prefer cheaper insulin drug from Viatris
RE
10/15SANOFI : New long-term data reinforcing promising safety and efficacy profile of brain-pen..
PU
10/15Sanofi Announces New Long-Term Data Reinforcing Promising Safety and Efficacy Profile o..
CI
10/14SANOFI : Goldman Sachs keeps its Buy rating
MD
10/14SANOFI : JP Morgan keeps its Buy rating
MD
10/13SANOFI : Update from Sanofi regarding Kevzara (sarilumab) - Supply constraints anticipated..
AQ
10/13SANOFI : Says Multiple Sclerosis Drug Well-Tolerated at One-Year Mark of Phase 2b Extensio..
MT
10/13SANOFI : Multiple Sclerosis Drug Remains Tolerable After One Year In Extension Study
MT
More news
Analyst Recommendations on SANOFI
More recommendations
Financials
Sales 2021 37 358 M 43 505 M 43 505 M
Net income 2021 6 037 M 7 031 M 7 031 M
Net Debt 2021 8 894 M 10 358 M 10 358 M
P/E ratio 2021 17,2x
Yield 2021 3,99%
Capitalization 104 B 121 B 121 B
EV / Sales 2021 3,01x
EV / Sales 2022 2,75x
Nbr of Employees 99 412
Free-Float 88,4%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 82,63 €
Average target price 104,90 €
Spread / Average Target 26,9%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI4.99%120 688
JOHNSON & JOHNSON4.12%431 385
ROCHE HOLDING AG15.84%337 562
NOVO NORDISK A/S57.04%239 813
PFIZER, INC.12.25%235 986
ELI LILLY AND COMPANY43.51%219 674